A signal no one
was looking for.
Science rarely announces its breakthroughs. More often, they arrive as a quiet inconsistency — a number that doesn't add up, a pattern that shouldn't be there.
Something didn't fit.
Studying cancer cell metabolism, Dr. Johannes Coy noticed that certain tumor cells were processing glucose through an unexpected pathway — not a mutation, not an error, but a deliberate biological strategy for survival and unchecked growth.
What if metabolism was the real target?
While the scientific mainstream focused on genomics, Dr. Coy followed a different thread: the enzyme at the center of this metabolic shift. He named it TKTL1 — and spent years making the case that disrupting it could matter clinically.
From insight to institution.
Tavargenix was founded to do what individual scientists cannot: protect a discovery, fund its translation, and carry it through the long road from hypothesis to therapy.
"The data kept pointing somewhere no one wanted to look. Most researchers moved on. I stayed."— Dr. Johannes Coy, Founder, Tavargenix
Why this still matters
At a time when cancer research focused almost exclusively on genetic mutations, the discovery of TKTL1 opened an entirely new dimension: metabolic reprogramming as a therapeutic target. Today, that once-dismissed hypothesis has become a recognised field of oncology research.